Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 2/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 6/20 | 0.44 |
| ▸ | BCR | P11274 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19380740 | 0.85 | DHFR (0.55) | DHFRKCNH2SCN5ASCN9AABL1 | |
| SCHEMBL1706290 | 0.85 | DHFR (0.55) | DHFRKCNH2SCN5ASCN9AABL1 | |
| SCHEMBL1702461 | 0.85 | DHFR (0.53) | DHFRKCNH2SCN5ASCN9AABL1 | |
| SCHEMBL16388751 | 0.84 | DHFR (0.54) | DHFRKCNH2SCN5ASCN9AABL1 | |
| SCHEMBL1705361 | 0.84 | DHFR (0.54) | DHFRKCNH2SCN5ASCN9AABL1 | |
| Obefazimod SCHEMBL1705888 | 0.84 | DHFR (0.54) | DHFRKCNH2SCN5ASCN9AABL1 | |
| Obefazimod SCHEMBL29157012 | 0.83 | DHFR (0.53) | DHFRKCNH2SCN5ASCN9AABL1 | |
| Obefazimod SCHEMBL30729382 | 0.83 | DHFR (0.53) | DHFRKCNH2SCN5ASCN9AABL1 | |
| SCHEMBL18034847 | 0.82 | DHFR (0.52) | DHFRKCNH2SCN5ASCN9AABL1 | |
| SCHEMBL15889170 | 0.81 | SYK (0.40) | DHFRMAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440546-B1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | ABIVAX (FR) | 2022-12-28 | — | — | EP | claimed |
| EP-2440547-B1 | New chemical molecules that inhibit the splicing mechanism for the treatment of diseases resulting from splicing defects | ABIVAX (FR) | 2022-11-30 | — | — | EP | claimed |
| EP-3517534-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | ABIVAX (FR) | 2019-07-31 | — | — | EP | claimed |
| US-10017498-B2 | Compounds useful for treating AIDS | ABIVAX (FR) | 2018-07-10 | — | — | US | claimed |
| US-9827237-B2 | Compounds useful for treating diseases caused by retroviruses | ABIVAX (FR) | 2017-11-28 | — | — | US | claimed |
| US-20160151348-A1 | COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | ABIVAX (FR) | 2016-06-02 | — | — | US | claimed |
| EP-3016656-A1 | BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | ABIVAX (FR) | 2016-05-11 | — | — | EP | claimed |
| CN-105530938-A | Compounds for the treatment of diseases caused by retroviruses | ABIVAX | 2016-04-27 | — | — | CN | claimed |
| US-20150307478-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | UNIVERSITE DE MONTPELLIER (FR) | 2015-10-29 | — | — | US | claimed |
| CN-104945378-A | Compounds for the treatment of premature aging and especially premature aging | ABIVAX | 2015-09-30 | — | — | CN | claimed |
| US-20140080831-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE (FR) | 2014-03-20 | — | — | US | claimed |
| US-20120329796-A1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | SOCIETE SPLICOS (FR) | 2012-12-27 | — | — | US | claimed |
| US-20120283265-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIETE SPLICOS (FR) | 2012-11-08 | — | — | US | claimed |
| US-20120277230-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | SOCIETE SPLICOS (FR) | 2012-11-01 | — | — | US | claimed |
| CN-102625804-A | Compounds for the treatment of AIDS | SPLICOS SOC | 2012-08-01 | — | — | CN | claimed |
| CN-102596935-A | Compounds for the treatment of premature aging and especially premature aging | SPLICOS SOC | 2012-07-18 | — | — | CN | claimed |
| CN-102574835-A | Compounds for the treatment of cancer | SPLICOS SOC | 2012-07-11 | — | — | CN | claimed |
| EP-2440545-A2 | COMPOUNDS USEFUL FOR TREATING CANCER | Société Splicos (FR) | 2012-04-18 | — | — | EP | claimed |
| WO-2010143168-A2 | COMPOUNDS USEFUL FOR TREATING CANCER | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | claimed |
| WO-2010143170-A2 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017498-B2 | Compounds useful for treating AIDS | NR1H3, NR1H2, NR1H4 | DHFR 186/4885KCNH2 1393/4885SCN5A 2609/4885 |
| US-20120283265-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | CBR1, CNR1, CBR3 | DHFR 128/4885KCNH2 2022/4885SCN5A 2740/4885 |
| US-20120277230-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | CBR1, CBR3, NCOR1 | DHFR 132/4885KCNH2 2283/4885SCN5A 2465/4885 |
| US-20120329796-A1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | NR2C2, NCOR2, NR4A2 | DHFR 1318/4885KCNH2 3686/4885SCN5A 3727/4885 |
| US-20150307478-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | NR1H3, NR1H2, NR1H4 | DHFR 186/4885KCNH2 1393/4885SCN5A 2609/4885 |
| US-20160151348-A1 | COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | RCOR1, CBR1, RCOR3 | DHFR 195/4885KCNH2 1466/4885SCN5A 3064/4885 |
| US-20140080831-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | NR1H4, NR1H3, NCOR1 | DHFR 376/4885KCNH2 2386/4885SCN5A 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.